Jing Chen

Dr. Jing Chen


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DHDongsheng Hong
Dongsheng Hong
LBLing Bi
Ling Bi
JZJun Zhou
Jun Zhou
YTYinghui Tong
Yinghui Tong
QZQingwei Zhao
Qingwei Zhao
XLXiaoyang Lu
Xiaoyang Lu
Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors

1 May 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZYZiqi Ye
Ziqi Ye
JCJie Chen
Jie Chen
ZXZixue Xuan
Zixue Xuan
WYWenchao Yang
Wenchao Yang
JCJing Chen
Jing Chen

Background:
Administration of subcutaneous (SC) bortezomib in patients with multiple myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient evidence to support the use of SC bortezomib as a standard of care. Methods: A systematic review of 4 randomized controlled trials and 8 retrospective trials comparing SC to intravenous (IV) bortezomib among 1,857 MM patients was performed. Embase, PubMed, Clinical Trials.gov, Cochrane Library and reference lists were searched for relevant studies from inception until August 2018. Outcomes of interest included 1-year overall survival (OS), 1-year progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs). Random events meta-analyses were performed. We also performed sensitivity analysis to examine whether the results of the meta-analysis were robust. Results: Compared to IV administration, SC bortezomib had a significantly lower incidence of some all-grade or grade 3–4 AE, such as peripheral sensory neuropathy, leukopenia and thrombocytopenia (p0.05). Conclusion: The data presented so far consistently show that SC bortezomib has become a standard of care for patients with MM.

16 August 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
LWLingjiao Wu
Lingjiao Wu
HYHanjin Yang
Hanjin Yang
XZXiaoChen Zhang
XiaoChen Zhang
SXSuZhen Xv
SuZhen Xv
QQQiong Qian
Qiong Qian
Background: Cellular senescence is a key element in the occurrence and progression of a variety of tumors. As a result, cellular senescence-related markers can be categorized based on the prognosis status of patients. Due to the heterogeneity and the complexity of the tumor microenvironment (TME), the long-term effectiveness of low-grade glioma (LGG) treatment remains a clinical challenge. Consequently, developing and refining effective treatment approaches to aid with LGG management is critical.Methods: Based on the expressions of cell senescence-related genes (CSRGs) acquired from the cellAge database, consensus clustering was utilized to identify stable molecular subtypes. Clinical features, immune infiltration, route modifications, and genetic changes of various subtypes were also assessed. Following that, the least absolute shrinkage and selection operator (LASSO) regression and univariate Cox regression analysis were used for developing the cell senescence-related risk score (CSRS) model. Finally, a correlation study of the CSRS model with molecular, immunological, and immunotherapy parameters was performed.Results: C1, C2, and C3, are the three senescence-related subtypes that were identified. Patients belonging to the C1 subtype had poor prognoses and a substantial proportion of them was in the grade G3. The differentially expressed genes (DEGs) among the three subtypes were used to develop the CSRS model. In both the training and independent validation cohort, the model had a high area under the receiver operating characteristic (ROC) curve in predicting the overall survival (OS) of patients. As a result, this model can predict clinical features and responses to immunotherapy in a variety of patients and it is a potential independent prognostic factor for LGG.Conclusion: This research discovered three LGG subtypes related to cell senescence and created a CSRS model for six genes. Cell senescence was highly associated with unfavorable prognosis in LGG. The CSRS model can be used to predict the prognosis of patients and identify patients who would benefit from immunotherapy.

22 May 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
YJYing Jin
Ying Jin
NLNan Li
Nan Li
RZRui Zheng
Rui Zheng
WMWei Mu
Wei Mu
XLXiang Lei
Xiang Lei
HSHongcai Shang
Hongcai Shang
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effectiveness and safety of benzodiazepines in the treatment of delirium (excluding delirium related to alcohol or benzodiazepines withdrawal) in all settings other than intensive care units (ICUs).

8 June 2020 in Research Square
Verified
Preprint
Open access
PDF file
HDHong Dongsheng
Hong Dongsheng
ZYZhang YanFang
Zhang YanFang
YZYe Ziqi
Ye Ziqi
JCJing Chen
Jing Chen
XLXiaoyang Lu
Xiaoyang Lu
Background: Breast cancer is the most commonly malignant cancers in women, and BIRC5 has been found to be overexpressed in a variety of human tumors. Its expression is associated with the prognosis of many cancers. However, whether BIRC5 mRNA could be used as an independent prognostic factor for breast cancer remains inconsistent in previous studies.Methods: Altered BIRC5 expression in normal tissue relative to various tumor tissue and in breast cancer patients with different molecular subtypes, clinical outcomes and chemotherapy responses were examined using the Oncomine, GOBO and Kaplan-Meier plotter datasets.Results: We found that many breast cancers had increased BIRC5 mRNA expression, and GOBO analysis showed that triple-negative cell lines displayed highest BIRC5 mRNA expression levels in the breast cancer cell line panel. Moreover, BIRC5 high mRNA expression was significantly associated with longer relapse-free survival (RFS) in all breast cancer patients. In particular, sub analysis revealed that high mRNA expression of BIRC5 was significantly associated with better survival in ER positive (HR = 2.05, p = 1e-16), but not in ER negative breast cancer (HR = 1.24, p = 0.1), furthermore, the results also demonstrated that BIRC5 high expression was significantly associated with longer RFS in luminal A (HR = 1.51, p = 3.1e-06) and luminal B (HR = 1.28, p = 0.026).Conclusions: In conclusion, BIRC5 is involved in the development and progression of breast cancer and may be a suitable prognostic marker for human breast cancer.